RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

Abstract Targeted therapy has achieved significant success in the treatment of non-small cell lung cancer (NSCLC), particularly in patients harboring common oncogenic driver mutations such as EGFR, KRAS, and ALK rearrangement. However, ~35–50% of NSCLC patients without tyrosine kinase mutation or re...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhengyu Zha, Chunxiao Liu, Meisi Yan, Cong Chen, Cheng Yu, Yaohui Chen, Chenhao Zhou, Lu Li, Yi-Chuan Li, Hiro Yamaguchi, Leiguang Ye, Tong Liu, Ying-Nai Wang, Heng-Huan Lee, Wen-Hao Yang, Li-Chuan Chan, Baozhen Ke, Jennifer L. Hsu, Lieming Ding, Dong Ji, Peng Pan, Yiran Meng, Yue Pu, Lunxu Liu, Mien-Chie Hung
Format: Article
Language:English
Published: Nature Publishing Group 2025-04-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02206-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-025-02206-x

Similar Items